Incidence and Predictors of Mortality Among Persons With Drug Resistant Tuberculosis, and HIV, Mozambique (2015-2020)

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Drug Resistance Tuberculosis (DRTB) is associated with a high risk of mortality during treatment. This study aims to describe the incidence and baseline characteristics associated with mortality in persons with drug resistance tuberculosis (P-DRTB) in a rural setting, in Mozambique. We analyzed cohort data collected retrospectively from paper medical files and electronic medical records of persons with DRTB (P-DRTB) who were routinely treated at Carmelo Hospital of Chokwe (Gaza province, Mozambique), from 1st January 2015 to 31st December 2020. Kaplan-Meier survival curves and adjusted Cox regression analyses were used to model the time to death and associated factors of mortality. Overall, 151 P-DRTB contributed to a total number of 1812 person-months (PM) of treatment follow-up. The overall mortality rate was 1.9 per 100 person-months (95% confidence interval [CI]: 1.3–2.1). Adjusted Cox regression predicted higher risk of mortality in those treated with DRTB injectable SLD, (adjusted hazard ratio [aHR] 3.72, 95% CI 1.23–11.22, p = 0.020), had a parenchymal lesion with more than 50% fibrosis (aHR 3.06, 95% CI 1.38–6.79, p = 0.006), presented right ventricular dysfunction on the venous cardio ultrasound (aHR 3.18, 95% CI 1.15–8.83, p = 0.026), and manifested baseline hemoglobin (Hgb) = 8.0–9.9 g/dL as well Hgb < 7.9 g/dL (aHR 2.82, 95% CI 1.09–7.27, p = 0.032; aHR 3.06, 95%CI 1.24–7 .51, p = 0.015) respectively. However, lower risk of mortality was predicted in those who had an optimal immunovirological response to ART (aHR 0.18, 95% CI 0.04–0.93, p = 0.040). Kaplan-Meier analysis showed higher cumulative incidence of mortality after 3 months of follow-up, above 26% in those with immunovirological failure to ART therapy p = 0.006), 45% with Hgb < 7.9g/dL (p < 0.001), 23% in treated with injectables-based drugs (p = 0.03), 39% with parenchymal lesion > 50% fibrosis on the chest X-ray (test p = < 0.001), 56% with right ventricular dysfunction (p = 0.003). Mortality risk among P-DRTB was higher in those with anemia, injectable DRTB medications, lung lesions > 50% fibrosis, and right ventricular dysfunction.

Article activity feed